UC San Diego Sulpizio Cardiovascular Center — La Jolla, California

UC San Diego Sulpizio Cardiovascular Center is a clinical research site located in La Jolla, California, United States 92037.

Crixeo Clinical Trials Trust Score: 16/100 (FAILING). This profile has not yet been claimed by the site owner.

UC San Diego Sulpizio Cardiovascular Center has participated in 6 clinical trials with 2 currently active.

Therapeutic areas: Critical Limb Ischemia, Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma.

Sponsors: Carelon Research, Pfizer, Vifor (International) Inc..

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in La Jolla

Browse all research sites in California · View every site in La Jolla

Sponsor Feasibility Report

Trust Score: 16/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for UC San Diego Sulpizio Cardiovascular Center?

UC San Diego Sulpizio Cardiovascular Center has a Crixeo Trust Score of 16/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has UC San Diego Sulpizio Cardiovascular Center conducted?

UC San Diego Sulpizio Cardiovascular Center has 6 clinical trials on record, with 2 currently active. Their work covers Critical Limb Ischemia, Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma.

Is UC San Diego Sulpizio Cardiovascular Center accredited by Crixeo Clinical Trials?

UC San Diego Sulpizio Cardiovascular Center has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about UC San Diego Sulpizio Cardiovascular Center?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.